Atorvastatin mitigates CI-AKI by suppressing the TLR4–MyD88–NF-κB signaling pathway, enhancing renal tubular epithelial cell activity, reducing cellular damage, and inhibiting both pyroptosis and inflammatory responses (Yue et al., 2023). This evidence concerns the gene TLR4 and acute kidney injury.